Eli Lilly recently acquired a smaller biotech for its promising investigational pain medication. The company generates strong ...

Just over six months into its dual launch across Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (axSpA), UCB’s Bimzelx (bimekizumab) is demonstrating meaningful ...

The Chicago native will screen the cult classic ‘Bound’ this week as part of Sapphopalooza. “Our films are remaining relevant ...

GLP-1 drugs like Ozempic are revolutionizing diabetes care. But they’re also making users less likely to drink alcohol. That ...

Advanz Pharma secures exclusive rights from Alvotech to commercialize three biosimilar candidates in Europe in addition to previously partnered programs The agreement includes proposed biosimilars to ...

Doctors are also seeing success in treating people with certain liver diseases. Isaacs prescribes GLP-1s for people with a ...

GLP-1 drugs like Ozempic show widespread promise beyond weight loss/diabetes, but cost and supply limit broader adoption.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Eli Lilly is a leading pharmaceutical company that has garnered ... Older medicines, such as cancer medicine Verzenio and immunosuppressant Taltz, continue to help drive top-line growth. And amid the ...

Eli Lilly, meanwhile, got a second tirzepatide drug ... while its sixth-best-selling drug Taltz is used to treat autoimmune diseases. Meanwhile, it currently has a plethora of drugs in clinical ...

Eli Lilly's once-weekly insulin product just aced phase 3 studies. The company will battle its eternal rival, Novo Nordisk, in this market. Eli Lilly's prospects look incredibly strong regardless ...